Prognostic value of the Fas/Fas ligand system in breast cancer

Fas and its ligand (FasL) are known to play a crucial role in the genetically controlled mechanism of cell death, and their deregulation in cancer cells is involved in the immune escape of the tumor. The aim of this review is to analyze the current knowledge on the prognostic value of Fas/FasL in breast cancer patients. Both the results of other authors and our own experiences indicate that the lack of Fas ligand, and particularly Fas, is related to a significantly worse prognosis. It probably results from the resistance of Fas-deficient breast tumors to the mechanisms of apoptosis. On the other hand, some results suggest that the Fas/FasL-dependent mechanisms of tumor spread may be different for various target tissues. The expression of the Fas/Fas-ligand system has potential prognostic application in view of current knowledge, and consequently should be considered as an additional prognostic factor in breast cancer patients.

[1]  D. Duś,et al.  Fas and Fas ligand as prognostic factors in human breast carcinoma. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[2]  L. Young,et al.  Inhibition of Metalloproteinase Cleavage Enhances the Cytotoxicity of Fas Ligand1 , 2003, The Journal of Immunology.

[3]  M. Mottolese,et al.  Prognostic relevance of altered Fas (CD95)‐system in human breast cancer , 2000, International journal of cancer.

[4]  A. Thorburn,et al.  Death receptor-induced cell killing. , 2004, Cellular signalling.

[5]  A. Mori,et al.  Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer , 2005, International Journal of Colorectal Disease.

[6]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[7]  D. Duś,et al.  Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. , 2007, Anticancer research.

[8]  T. Rafnar,et al.  Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells , 2000, British Journal of Cancer.

[9]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[10]  F. Shanahan,et al.  Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege , 1999, Clinical Diagnostic Laboratory Immunology.

[11]  K. Chayama,et al.  Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. , 2004, Oncology reports.

[12]  T. Lehnert,et al.  Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease , 2005, Gut.

[13]  K. Isselbacher,et al.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Wei-Chen Lee,et al.  Prognostic Impact of Fas Ligand on Hepatocellular Carcinoma after Hepatectomy , 2004, World Journal of Surgery.

[15]  M. Toi,et al.  Circulating soluble Fas concentration in breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  K Takahashi,et al.  Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression , 2005, British Journal of Cancer.

[17]  H. Stein,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0202 , 2022 .

[18]  T. Reimer,et al.  FasL:Fas ratio--a prognostic factor in breast carcinomas. , 2000, Cancer research.

[19]  G. Rennert,et al.  Apoptosis, proliferation, and Fas (APO‐1, CD95)/Fas ligand expression in medullary carcinoma of the breast , 2000, The Journal of pathology.

[20]  L. Qin,et al.  The prognostic molecular markers in hepatocellular carcinoma. , 2002, World journal of gastroenterology.

[21]  Mamie Yu,et al.  Diagnostic and prognostic value of fas and telomeric-repeat binding factor-1 genes in adrenal tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[22]  E. Russell,et al.  Fas expression and function in normal and malignant breast cell lines. , 1996, Cancer research.

[23]  T. Eberlein,et al.  Fas (CD95/APO‐1) and Fas ligand expression in normal pancreas and pancreatic tumors , 2002, Cancer.

[24]  M. Mottolese,et al.  Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy , 2004, Clinical Cancer Research.

[25]  M. Savitskaya,et al.  Mechanisms of apoptosis , 2015, Biochemistry (Moscow).

[26]  B. A. Davis,et al.  Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand , 2003, Cancer Chemotherapy and Pharmacology.

[27]  John Calvin Reed,et al.  The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  G. Sakamoto,et al.  Time dependency of the influence of prognostic factors on relapse in breast cancer , 1993, Cancer.

[29]  D. Rossi,et al.  Messengers of cell death: apoptotic signaling in health and disease. , 2003, Haematologica.

[30]  K. Koretz,et al.  Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium , 1994, International journal of cancer.